Vertebral Fractures Following Discontinuation of Denosumab: a Post-hoc Analysis of the Randomized Placebo-controlled FREEDOM Trial and its Extension
J Bone Miner Res. 2017 Nov 4. doi: 10.1002/jbmr.3337 Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk. Denosumab discontinuation increases BTMs 3 months after a scheduled dose is omitted, reaching above-baseline levels by … Leer más